BioArctic AB's (publ) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecanemab), using a subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results